Why the study?
Do point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel or aspirin in patients with DES thrombosis compared to matched controls?
Do point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel or aspirin in patients with DES thrombosis compared to matched controls?
Point-of-care assays demonstrate reduced platelet responsiveness to clopidogrel, but not aspirin, in patients who experience DES thrombosis, suggesting a potential role for prospective testing.
No takes yet. Share an insight, caveat, or question.
May support point-of-care testing to identify clopidogrel nonresponders at DES thrombosis risk; leaves open whether assay-guided therapy improves outcomes.
Hobson et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: